Effect of repeated transcranial magnetic stimulation on serum BDNF in elderly patients with mild cognitive impairment
QUAN Qingyun1, WANG Xiaoyan1, ZHANG Yu1, LEI Zhuoyue2
1. Wards for Old Cadres, Shaanxi Provincial Corps Hospital of Chinese People's Armed Police Force, Xi'an 710054, China; 2. Health Team of Yulin Detachment Shaanxi Provincial Corps of Chinese People's Armed Police Force, Yulin 719000,China
Abstract：Objective To observe the effect of repeated transcranial magnetic stimulation (rTMS) on serum brain-derived neurotrophic factor (BDNF) in elderly patients with mild cognitive impairment (MCI). Methods A total of 65 elderly patients with MCI who were admitted to Provincial Corps Hospital of Chinese People's Armed Police Force from January 2022 to October 2023 were included in the study, and divided into control group (n=32) and treatment group (n=33) by random number table method. In the control group,40mg of ginkgo biloba extract was taken orally (3 times/day) plus sham stimulation, while the treatment group received ginkgo biloba extract (manufacturer, specification, usage and dosage were the same as the control group) plus rTMS, and the primary disease was treated simultaneously in both groups. Serum BDNF was measured before treatment and 4 weeks after treatment, respectively, the clinical efficacy of the two groups before and after treatment was compared using the Simple Mental State Intelligence Scale (MMSE) and Montreal Cognitive Assessment Scale (MoCA) scores. Results After treatment, MMSE [(24.58±1.640) vs. (22.50±1.344)] and MoCA scores [(24.03±1.51) vs. (22.03±1.28)] in the treatment group were higher than those in the control group. MMSE [(24.58±1.64) vs. (22.97±1.78)] and MoCA [(24.03±1.51) vs. (21.88±1.75)] scores of the treatment group were significantly higher after treatment than those before treatment, and the differences were statistically significant (P＜0.05). After treatment, the serum BDNF level in the treatment group was significantly higher than that of the control group [(9.54±1.64) vs. (8.28±1.91)], and the serum BDNF level of the treatment group was higher than that before treatment [(9.54±1.64) vs. (7.93±1.62)], with statistically significant differences (P＜0.05). Conclusions Serum BDNF level is closely related to cognitive impairment in the elderly. rTMS therapy can increase the BDNF the level of BDNF in senile MCI patients and improve cognitive function, which is worthy of clinical promotion.
权青云, 王小艳, 张愉, 雷卓越. 重复经颅磁刺激治疗对老年轻度认知功能障碍患者血清脑源性神经营养因子的影响[J]. 武警医学, 2025, 36(3): 205-207.
QUAN Qingyun, WANG Xiaoyan, ZHANG Yu, LEI Zhuoyue. Effect of repeated transcranial magnetic stimulation on serum BDNF in elderly patients with mild cognitive impairment. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(3): 205-207.
Folstein M F, Folstein S E, McHugh P R. Minimental state.Apractical method for grading the cognitivestate of patients for theclinician[J].J Psychiatr Res,1975,12(3):189-198.
[6]
Nasreddine Z S,Phillips N A,Bedlirian V,et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment[J].J Am Geriatr Soc,2005,53(4):695-699.
[7]
Song W, Du B, Xu Q, et al. Low-frequency transcranial magnetic stimulation for visual spatial neglect:a pilot study[J].J Rehabil Med,2009,41(3):162-165.
Petersen R C.Mild cognitive impairment: transition between aging and alzheimer′s disease[J]. Neurologia,2000,15(3):93-101.
[11]
Dodge H H, Zitzelberger T, Oken B S,et al.A randomized placebo-controlled trial of ginkgo biloba for the prevention of cognitive decline[J].Neurology,2008,70(19):1809-1817.
Valero-Cabre A, Amengual J L, Stengel C,et al.Trancranial magnetic stimulation in basic and clinical neuroscience:a comprehensive review of fundamental principles and novel insights[J].Neurosci Biobehav Rev,2017,83(3):381-404.
[15]
Giacomo K.Do studies on cortical plasticity provide a rationale or using non-invasive brain stimulation as a treatment for prakinson's disease patients[J].Front Neurol,2013,180(4):1-4.
[16]
Wang F,Geng X,Tao H Y,et al.The restoration after repetitive transcranial magnetic stimulation treatment on cognitive ability of vascular dementia rats and its impacts on synaptic plasticity in hippocampal CA1 area[J].J Mol Neurosci,2010,41(1):145-155.
[17]
Palasz E,Wysocka A,Gasiorowska A,et al.BDNF as a promising therapeutic agent in parkinson's disease[J]. Int J Mol Sci,2020,21(3):1170-1193.
[18]
Rauti R,Cellot G,D'Andrea P,et al.BDNF impacton synaptic dynamics: extra or intracellular long-term release differently regulates cultured hippocampal synapses[J].Mol Brain,2020,13(1):43-59.
[19]
Wang M,Xie Y,Qin D.Proteolytic cleavage of proBDNF to mBDNF in neuropsychiatric and neurode generative diseases[J].Brain Res Bull,2021,166,(1):172-184.
2025, Vol. 36 
